key: cord-0999173-hnsqrgio
authors: Sanli, Deniz Esin Tekcan; Altundag, Aytug; Kandemirli, Sedat Giray; Yildirim, Duzgun; Sanli, Ahmet Necati; Saatci, Ozlem; Kirisoglu, Ceyda Erel; Dikensoy, Oner; Murrja, Edvin; Yesil, Atakan; Bastan, Serdar; Karsidag, Tamer; Akinci, Ibrahim Ozkan; Ozkok, Sezen; Yilmaz, Eren; Tuzuner, Filiz; Kilercik, Meltem; Ljama, Taner
title: Relationship between disease severity and serum IL-6 levels in COVID-19 anosmia
date: 2020-10-28
journal: Am J Otolaryngol
DOI: 10.1016/j.amjoto.2020.102796
sha: c10a28c21e67623594d24daf991a5cca406dd663
doc_id: 999173
cord_uid: hnsqrgio

BACKGROUND: An association between IL-6 levels and cytokine storm syndrome in COVID-19 patients has been suggested. Cases with higher IL-6 levels have more rapid progression and a higher complication rate. On the other hand, COVID-19 cases with anosmia have a milder course of the disease. OBJECTIVE: We aimed to investigate whether there is a relationship between serum IL-6 levels and presence of anosmia in COVID-19 patients. METHODS: Patients with a confirmed diagnosis of COVID-19 based on laboratory (PCR) were stratified into two groups based on presence of olfactory dysfunction (OD). In all cases with and without anosmia; psychophysical test (Sniffin' Sticks test) and a survey on olfactory symptoms were obtained. Threshold (t) – discrimination (d) – identification (i), and total (TDI) scores reflecting olfactory function were calculated. Clinical symptoms, serum IL-6 levels, other laboratory parameters, and chest computed tomography (CT) findings were recorded. RESULTS: A total of 59 patients were included, comprising 23 patients with anosmia and 36 patients without OD based on TDI scores. Patients with anosmia (41.39 ± 15.04) were significantly younger compared to cases without anosmia (52.19 ± 18.50). There was no significant difference between the groups in terms of comorbidities, smoking history, and symptoms including nasal congestion and rhinorrhea. Although serum IL-6 levels of all patients were above normal values (7 pg/mL), patients with anosmia had significantly lower serum IL-6 levels (16.72 ± 14.28 pg/ml) compared to patients without OD (60.95 ± 89.33 pg/ml) (p = 0.026). CONCLUSION: Patients with COVID-19 related anosmia tend to have significantly lower serum levels of IL-6 compared to patients without OD, and the lower IL-6 levels is related to milder course of the disease. With the effect of low cytokine storm and IL-6 level, it may be said that anosmic cases have a milder disease in COVID-19.

Patients with COVID-19 mainly presents with cough and fever and may have parenchymal changes on chest computed tomography (CT). Anosmia (loss of smell) and dysgeusia (altered sensation of taste) have been reported in 33-80% of patients with COVID-19 [1, 2] .

Anosmia/hyposmia and dysgeusia are reported to be associated with other upper respiratory tract infections with a rate of 11-40%, mainly due to nasal congestion and secretions [3, 4] The main differences between COVID-19 related anosmia and anosmia seen in other upper respiratory tract infections are sudden onset irrespective of presence of nasal congestion/obstruction and possible correlation with neurological symptoms in COVID-19 disease [5] [6] [7] [8] .

Exact pathophysiology of anosmia in COVID-19 infection has not been firmly established.

Angiotensin-2 (ACE2) receptors have been identified as a cellular receptor for SARS-CoV-2, which are highly expressed in olfactory mucosa. A plausible mechanism is direct extension through the nasal mucosa with direct neuropathic damage in olfactory filia and olfactory bulb [9, 10] . Neurotropism with involvement of olfactory nuclei has been proposed as an additional mechanism for anosmia/hyposmia [11] . This neurotropism can also result in brainstem involvement which might be responsible for the respiratory distress [11, 12] . Another potential route of spread may involve initial uptake at alveoli through ACE2 receptors, followed by J o u r n a l P r e -p r o o f hematogenous spread and intracranial involvement due to blood brain barrier disruption [5, 13] Anosmia/hyposmia can be the initial and only symptom of COVID-19 infections, and usually show improvement over a 1-2-week period without treatment in majority of cases [8, 14, 15] .

COVID-19 anosmia is usually seen in younger age group with female predominance, patients have milder symptoms with some cases being asymptomatic [16] . In this aspect, anosmia is an important symptom for suspecting COVID-19 disease and appropriate patient triage and isolation.

IL-6 is an important pro-inflammatory cytokine and has been associated with more rapid disease progression and a higher complication rate in COVID-19 cases. Accumulated evidence so far has demonstrated cytokine storm syndrome is associated more severe disease and complications [17] . On the other hand, COVID-19 anosmia cases have milder disease.

Based on these observations, we aimed to investigate the relationship between IL-6 levels and presence of COVID-19 related anosmia. Secondary aim of the study was to assess the clinical and radiological prognosis in cases with COVID-19 related anosmia.

Study Population: Institutional review board approval and informed consent were obtained from Acıbadem University (2020-12/26). This was a retrospective study including patients with a confirmed diagnosis of COVID-19 based on laboratory (PCR) and radiological (CT) features between March and June 2020. Laboratory and radiological data obtained at initial admission to the hospital within the first week of symptoms onset were reviewed. Patients with a serum IL-6 available were included in the study. Subsequently, patients were contacted by phone and olfactory symptoms were reviewed using a questionnaire. Patients were J o u r n a l P r e -p r o o f stratified into two groups based on olfactory symptoms: Group 1: cases with no OD during the course of COVID-19 infection, and Group 2: cases with OD during the course of COVID-19 infection.

All patients included in the study had serum IL-6 levels at the time of admission to the hospital. These first values were included in the calculation since control laboratory parameters were not examined in cases with mild clinical course. In cases with severe clinical course, IL-6 levels, which were higher on laboratory control within an average of 10±6 days compared to the clinical course, were included in the calculation. anosmic if <16.5 [19] . The applicability of "Sniffin' Sticks" test for target population has been previously validated [20] .

Survey: All patients were contacted via phone for a survey related to anosmia symptoms. This survey focused on subjective scaling of anosmia severity, duration and change over time. However, headache and myalgia were significantly more prevalent in cases with anosmia. There was no significant relationship between TDI scores and IL-6 levels in patients with anosmia (p>0.05) (Figure 2 ).

The important data of the study are arranged as a flowchart in Figure 3 .

The results of this study showed that, although increased relative to normal serum IL-6 levels were detected in both groups, mean IL-6 levels were significantly higher in subjects without OD than in patients with anosmia. Additionally, chest CT findings were milder and more subtle in anosmia cases with a lower rate of progression and more rapid radiological recovery. value of 80 pg/mL for mortality [29, 31] .

Previously COVID-19 related anosmia was suggested to be related with milder disease course [16] . One study showed that the percentage of anosmia was lower in hospitalized patients [36] . Similarly, in our study, systemic serum IL-6 levels were found above normal levels in anosmic cases, however IL-6 levels did not reach a level as high as seen in cytokine storm syndrome. We did not obtain nasal-olfactory biopsies due to risk of exposure, and did not show a direct relation between inflammatory markers in olfactory epithelium and OD. To the best of our knowledge, there is no study investigating IL-6 levels in nasal mucosa or olfactory epithelium in COVID-19 anosmia. This association between nasal mucosal IL-6 levels and COVID-19 anosmia could be investigated in further studies separately or in combination with systemic IL-6 levels. We think that there is a more severe nasal cytokine storm in COVID-19 anosmia which leads to mucosal, epithelial and receptor damage mediated via proinflammatory cytokines. In this regard, cases who could summon a response to the virus at olfactory epithelium level would have a milder systemic disease but suffer from OD. We propose that olfactory epithelium is the initial site of inoculation and first line of defense against the virus.

Major limitation of our study is limited number of cases due to single-center nature of the study. A second major limitation is that laboratory markers and radiological evaluations were J o u r n a l P r e -p r o o f obtained at different time points of disease stage which incorporates heterogeneity to the study population.

In conclusion, our study supports the observations that patients with COVID-19 anosmia have milder disease course as demonstrated by clinical, laboratory and imaging findings. COVID-19 anosmia cases had lower IL-6 levels compared to COVID-19 patients without olfactory dysfunction which might be an underlying mechanism for the difference in clinical course.

Further studies to assess the relationship between other cytokines responsible for cytokine storm syndrome and anosmia are needed to better define the underlying etiologies and prediction of prognosis. 

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Anosmia: A marker of infection by the new corona virus

Olfactory disorders following upper respiratory tract infections

Anosmia in COVID-19: Mechanisms and Significance. Chem Senses. Epub ahead of print 17

Association of chemosensory dysfunction and COVID-19 in patients presenting with influenza-like symptoms

Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional Study

Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study

Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts

Non-neural exporessio of SARSCoV-2 entry genes in the olfactory epithelium suggests mechanisms of underlying anosmia

Epub ahead of print 28

Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43

Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Long-term follow-up of olfactory loss secondary to head trauma and upper respiratory tract infection

COVID-19 Anosmia Reporting Tool: Initial Findings

Early recovery following new onset anosmia during the COVID-19 pandemic -an observational cohort study

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Endorsed by the Society of Thoracic Radiology, the American College of Radiology, and RSNA -Secondary Publication

Multicenter investigation of 1,036 subjects using a standardized method for the assessment of olfactory function combining tests of odor identification, odor discrimination, and olfactory thresholds

The applicability of the "Sniffin' Sticks" olfactory test in a Turkish population

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Constitutive Inflammatory Cytokine Storm: A Major Threat to Human Health

Immunotherapeutic implications of IL-6 blockade for cytokine storm

Interleukin-6 as a potential biomarker of COVID-19 progression

Multiple enzyme release, inflammation storm and hypercoagulability are prominent indicators for disease progression in COVID-19: a multi-centered, correlation study with CT imaging score. SSRN. Epub ahead of print 22

Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients

Dysregulation of Immune Response in Patients With Coronavirus

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Elevated interleukin-6 and severe COVID-19: A metaanalysis

Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Objective olfactory evaluation of self-reported loss of smell in a case series of 86 COVID-19 patients

The Link Between Cytokine Levels and Loss of Olfaction in Chronic Rhinosinusitis

Proinflammatory Cytokines in the Olfactory Mucosa Result in COVID-19 Induced Anosmia

Interleukin 6 in hyposmia